Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;65(9):1101-1105.
doi: 10.11406/rinketsu.65.1101.

[New drugs for the treatment of primary immune thrombocytopenia]

[Article in Japanese]
Hirokazu Kashiwagi  1   2
Affiliations

[New drugs for the treatment of primary immune thrombocytopenia]

[Article in Japanese]
Hirokazu Kashiwagi. Rinsho Ketsueki. 2024.

Abstract

Two thrombopoietin receptor agonists (eltrombopag and romiplostim), rituximab or splenectomy have been recommended for the treatment of glucocorticoid-resistant ITP in Japanese guidelines. In addition, the Syk inhibitor fostamatinib and FcRn inhibitor efgartigimod were approved in Japan for refractory ITP in 2023 and 2024, respectively. Clinical trials have also reported promising results for the new thrombopoietin receptor agonist avatrombopag, the BTK inhibitor rilzabrutinib, and the C1s inhibitor sutimlimab. These developments will usher in a new era in the treatment of ITP.

Keywords: Avatrombopag; Efgartigimod; Fostamatinib; Rilzabrutinib.

PubMed Disclaimer

Publication types

MeSH terms

Substances